Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-GD2 in refractory or recurrent neuroblastoma
NCT02765243Phase 1Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2-specific 4SCAR-T cells in neuroblastoma, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Number of patients with adverse events at 1 year. Started Jan 2016; status: completed.
02
Drugs
GD2-specific 4SCAR-T cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02765243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765243.